With the $250 service, Color is hoping to broaden access to genetic testing and make it easier for researchers to incorporate genetics in their studies.
Launching a diverse product pipeline will also test Helix's ability to manage the challenges of providing genomics interpretations to a broad consumer audience.
The consumer genomics firm Helix will use an FDA-cleared device from OraSure's subsidiary DNA Genotek for collecting DNA samples from customers.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The company has decided to put its direct-to-consumer sequencing campaign on hold after receiving a letter from the FDA.
The new company believes it can be the dominant clearinghouse for genome analysis apps or other tools, with free and unlimited storage of users' genomic data.
As many as 10,000 Nevadans will get free genetic testing through a large population health study being conducted by non-profit care network Renown Health.
Early backers can get their genome or exome sequenced at discounted rates of $999 and $399, respectively, limited to the first 10 and 50 users in each case.
The company has developed a panel of 15 genes, identified from scientific literature, that specifically link to an athlete's potential to respond to power or endurance training.
Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.